[go: up one dir, main page]

AU2596700A - Promotion or inhibition of angiogenesis and cardiovascularization - Google Patents

Promotion or inhibition of angiogenesis and cardiovascularization

Info

Publication number
AU2596700A
AU2596700A AU25967/00A AU2596700A AU2596700A AU 2596700 A AU2596700 A AU 2596700A AU 25967/00 A AU25967/00 A AU 25967/00A AU 2596700 A AU2596700 A AU 2596700A AU 2596700 A AU2596700 A AU 2596700A
Authority
AU
Australia
Prior art keywords
cardiovascularization
angiogenesis
promotion
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU25967/00A
Other languages
English (en)
Inventor
Kevin P. Baker
Napoleone Ferrara
Audrey Goddard
Austin L. Gurney
Kenneth J. Hillan
P. Mickey Williams
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/fr
Priority claimed from PCT/US1999/023089 external-priority patent/WO2000021996A2/fr
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/fr
Priority claimed from PCT/US1999/028409 external-priority patent/WO2000032778A2/fr
Priority claimed from PCT/US1999/028565 external-priority patent/WO2000037638A2/fr
Priority claimed from PCT/US1999/028564 external-priority patent/WO2000055319A1/fr
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2596700A publication Critical patent/AU2596700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU25967/00A 1999-03-08 1999-12-30 Promotion or inhibition of angiogenesis and cardiovascularization Abandoned AU2596700A (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
WOUS9905028 1999-03-08
PCT/US1999/005028 WO1999046281A2 (fr) 1998-03-10 1999-03-08 Nouveaux polypeptides et acides nucleiques les codant
US13023299P 1999-04-21 1999-04-21
US60130232 1999-04-21
US13102299P 1999-04-26 1999-04-26
US60131022 1999-04-26
US13144599P 1999-04-28 1999-04-28
US60131445 1999-04-28
US13428799P 1999-05-14 1999-05-14
US60134287 1999-05-14
PCT/US1999/023089 WO2000021996A2 (fr) 1998-10-13 1999-10-05 Procedes et compositions inhibant la croissance des cellules neoplasiques
PCT/US1999/028313 WO2000032221A2 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
PCT/US1999/028409 WO2000032778A2 (fr) 1998-12-01 1999-11-30 Methodes et compositions permettant d'inhiber la croissance de cellules neoplasiques
PCT/US1999/028565 WO2000037638A2 (fr) 1998-12-22 1999-12-02 Methodes permettant d'inhiber la croissance de cellules neoplasiques
WOUS9928565 1999-12-02
PCT/US1999/028564 WO2000055319A1 (fr) 1999-03-12 1999-12-02 Procedes et compositions pour inhiber la croissance des cellules neoplasiques
PCT/US1999/031274 WO2000053752A2 (fr) 1999-03-08 1999-12-30 Activation ou inhibition de l'angiogenese et de la cardiovascularisation

Publications (1)

Publication Number Publication Date
AU2596700A true AU2596700A (en) 2000-09-28

Family

ID=27494842

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25967/00A Abandoned AU2596700A (en) 1999-03-08 1999-12-30 Promotion or inhibition of angiogenesis and cardiovascularization

Country Status (2)

Country Link
AU (1) AU2596700A (fr)
WO (1) WO2000053752A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579520B2 (en) * 1998-05-15 2003-06-17 Genentech, Inc. IL-17 related mammalian cytokine polypeptides (IL-17E)
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
DE19951960C2 (de) * 1999-10-28 2002-06-27 Gruenenthal Gmbh Verfahren zur Herstellung als Ulkustherapeutika geeigneter Benzimidazol-Derivate
ES2380958T3 (es) * 1999-12-23 2012-05-21 Genentech, Inc. Polipéptidos homólogos IL-17 y utilizaciones terapéuticas de los mismos
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2042597B1 (fr) * 2000-06-23 2014-05-07 Genentech, Inc. Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogénèse
FR2851249A1 (fr) * 2003-02-17 2004-08-20 Commissariat Energie Atomique Nouveau facteur soluble secrete par les cellules endotheliales des vaisseaux sanguins, capable d'inhiber le recrutement des cellules perivasculaires du type musculaire lisse et ses applications
BRPI0509420A (pt) 2004-04-14 2007-09-04 Genentech Inc método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico
US20090317400A1 (en) 2008-05-05 2009-12-24 Krzysztof Masternak Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof
RU2605318C2 (ru) 2009-05-05 2016-12-20 Новиммун С.А. Анти-il-17f антитела и способы их применения
BRPI1007706A2 (pt) 2009-05-08 2019-04-02 Genentech, Inc. anticorpo anti-egfl7, anticorpo biespecífico, ácido nucléico, vetor, célula hospedeira, composição, método para produzir um anticorpo anti-egfl7, método de redução ou inibição da angiogênese em um indivíduo, método de acentuação da eficácia de um agente antiangiogênese em um indivíduo e método de redução ou inibição da perfusão e permeabilidade de um tumor em um indivíduo
EP4007775A1 (fr) * 2019-08-02 2022-06-08 Orega Biotech Nouveaux anticorps il-17b
CN111526397A (zh) * 2020-03-30 2020-08-11 深圳市懿美莱科技有限公司 一种智能家庭网络播放器

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
MX9605109A (es) * 1994-04-26 1997-08-30 Childrens Medical Center Angiostatina y metodo de uso para la inhibicion de angiogenesis.
DE69834727T2 (de) * 1997-08-01 2007-01-25 Serono Genetics Institute S.A. 5' ests für sekretierte proteine die in verschiedenen geweben expremiert werden
JP2002504308A (ja) * 1997-11-22 2002-02-12 ハイセック インコーポレイテッド 胎児肝−脾臓のｃＤＮＡライブラリーから得られた新規ＥＧＦモチーフタンパク質
ES2312205T3 (es) * 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.

Also Published As

Publication number Publication date
WO2000053752A2 (fr) 2000-09-14
WO2000053752A3 (fr) 2000-12-21

Similar Documents

Publication Publication Date Title
AU2600800A (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU6465400A (en) Inhibition of action potentials
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU3791601A (en) Treatment of coal
AU2596700A (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU2567300A (en) Inhibition of angiogenesis with epigallocatechin-3-gallate
AU6566098A (en) Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
AUPQ429399A0 (en) Oxidized apolipoproteins and methods of use
AU9484398A (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU4369000A (en) Inhibition of complement action
IL140324A0 (en) Inhibition of transcription factor nf-kb
AU7601400A (en) Treatment and prevention of hepatic disorders
AU7271600A (en) Quinazolinone and azaquinazolinone derivatives
IL141537A0 (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU4440199A (en) Methods and compositions for inhibition of angiogenesis
AU5571799A (en) Angiogenesis inhibitors and uses thereof
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
AUPQ180499A0 (en) Beta-amyloid peptide inhibitors
AU2002215032A1 (en) Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof
EP1229913A4 (fr) 1-benzazepines substituees et leurs derives
AU2001251631A1 (en) Hydrazide and alkoxyamide angiogenesis inhibitors
AU1747100A (en) Promotion or inhibition of angiogenesis and cardiovascularization
HUP0301797A3 (en) Inhibition of angiogenesis and tumor growth
AU5646300A (en) Methods of stimulating angiogenesis
IL142742A0 (en) Promotion or inhibition of angiogenesis and cardiovascularization

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase